DUBLIN, Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business update on Tuesday, January 14, 2025, at 9:45 a.m. PST / 5:45 p.m. GMT.

A live audio webcast of the presentation may be accessed via the Investors section of the Jazz Pharmaceuticals website at . A replay of the webcast will be available on the website for 30 days following the conference.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit for more information.

Contacts:

Investors:
Jeff Macdonald
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
[email protected]
Ireland, +353 1 634 3211
U.S., +1 650 496 2717

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
[email protected]
Ireland, +353 1 637 2141
U.S., +1 215 867 4948

SOURCE Jazz Pharmaceuticals plc